HESI THRIVE
makes cancer patient quality of life an active research priority.
We are proud to launch the 2019 THRIVE grant awards here. A total of $225,000 will be awarded (4-6 grants)
. Letters of Intent are due October 19, 2018 at
http://www.hesithrive.org
. Awards announced January 11, 2019. Special thanks to THRIVE’s 2019 funders and partners: National Patient Advocate Foundation, Amgen, and HESI.
THRIVE’s seed grants catalyze translational research on when and how adverse effects occur and how to avoid or lessen them. In THRIVE’s first year, grantees progressed areas such as neuropathic pain associated with breast cancer therapy, adverse effects from immunotherapy, and cardiac dysfunction associated with chemotherapies used to treat childhood cancers.
In October 2019, we will also launch a global, public-private collaborative effort to innovate approaches for supporting the safety of oncologic therapies.
We anticipate an initial focus on translational models for immuno-oncology safety but may adopt additional projects. Findings will be made publicly available upon completion. To date, individuals from the following organizations have made initial commitments to the design and launch of this HESI program: The National Patient Advocate Foundation, Medstar Health in Washington, MD Anderson, USC Ellison Institute for Transformative Medicine, U.S. Food and Drug Administration, Abcam, Amgen, Bristol-Myers Squibb, Sanofi, Takeda, Taconic, and HESI.
